Relmada Therapeutics (RLMD) Misses Q3 EPS by 84c
Get Alerts RLMD Hot Sheet
Join SI Premium – FREE
Relmada Therapeutics (NASDAQ: RLMD) reported Q3 EPS of ($2.44), $0.84 worse than the analyst estimate of ($1.60).
As of September 30, 2021, the Company had cash and short-term investments of $88.1 million, compared to cash, cash equivalents, and short-term investments of approximately $117.1 million at December 31, 2021.
For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- FTI Consulting (FCN) Tops Q1 EPS by 40c
- Ladder Capital (LADR) Tops Q1 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!